541 results on '"Taïeb J."'
Search Results
102. O006 - La CHIP améliore-t-elle la survie des carcinoses d’origine gastrique : une étude monocentrique rétrospective comparative
103. PD-028 Retrospective analysis of impact of Köhne prognostic category and BRAF mutation status on survival in patients with RAS wild-type metastatic colorectal cancer treated with second-line FOLFIRI with/without panitumumab
104. PD-026 Survival outcomes in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) classified by Köhne prognostic category and BRAF mutation status: retrospective analysis of the PRIME study
105. Fission-fragment yields and prompt-neutron multiplicity for Coulomb-induced fission of $^{234,235}\mathrm{U}$ and $^{237,238}\mathrm{Np}$
106. LBA10 Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase III study
107. 651P DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: A multicenter propensity score matching study
108. 625P Efficacy and safety of the combination of encorafenib and cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: An AGEO real-world multicentre study
109. 614P Effect of KRASG12 mutations on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial
110. 613P Effect of prior use of anti-VEGF agents on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial
111. 567P Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients: Results from the PETACC 8 study
112. 553O Prognostic value of KRAS and BRAF mutations in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: An ACCENT/IDEA pooled analysis of 7 trials
113. Synthèse méthodique: intérêt de la chimiothérapie périopératoire dans la prise en charge des patients atteints d’un adénocarcinome du rectum résécable d’emblée (rapport abrégé)
114. Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers
115. SO-17 A new risk classification integrating ctDNA, CEA, and pTN stage for DFS prognosis and predictive value for treatment duration in stage III colon cancer
116. P-386 Novel data visualization and unsupervised machine learning techniques to support optimal management of toxicity profiles of encorafenib plus cetuximab in patients with BRAFV600E-mutant metastatic colorectal cancer
117. P-95 Long-term effectiveness results and prognostic predictors for overall survival from CIREL – the real-world multi-centre, observational cohort on irinotecan-eluting transarterial chemoembolization in CRLM
118. O-9 Health-related quality of life associated with trifluridine/tipiracil in combination with bevacizumab in refractory metastatic colorectal cancer: An analysis of the phase 3 SUNLIGHT trial
119. PCR117 Meaningful Change Thresholds in Patient-Reported Outcome Scores for Patients with Colorectal Cancer – A Systematic Literature Review
120. Measurements with the high flux lead slowing-down spectrometer at LANL
121. Orages rythmiques
122. Organisation and management of acute complete atrioventricular block in France: Results from a French multicentre national survey
123. Cancéro digest o.2 l’actualité en oncologie digestive Supplément á la lettre du cregg
124. Cancérodigest nℴ 1, Juin 2003, Supplément á la Lettre du CREGG
125. Tumeurs digestives : côlon — rectum
126. Evaporation residues produced in spallation of 208Pb by protons at [formula omitted]
127. Very heavy fission fragments produced in the spallation reaction 238U+ p at [formula omitted]
128. QT long acquis : un problème envahissant ?
129. Surgical treatment of peri-implantitis using mechanical debridement with or without an air abrasive device: A randomized, controlled clinical trial: P0486
130. Evidence for a New Compact Symmetric Fission Mode in Light Thorium Isotopes
131. Nuclide cross-sections of fission fragments in the reaction 208Pb + p at 500 A MeV
132. Recoil spectrometers for heavy-ion identification and secondary-beam production: Pushing the low-energy limit
133. FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Entérologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study
134. Les types d’insomnies chez les patients atteints de maladie Verneuil
135. Somnolence diurne excessive chez les patients adultes souffrant de dermatite atopique
136. Les types d’insomnies chez les patients atteints de dermatite atopique
137. LBA23 Avelumab versus standard second-line treatment chemotherapy in metastatic colorectal cancer (mCRC) patients with microsatellite instability (MSI): The SAMCO-PRODIGE 54 randomised phase II trial
138. 343P DPYD gene sequencing and in silico functionality prediction of polymorphisms in 3,471 colorectal cancer patients treated with fluoropyrimidine (FP)
139. 317MO Efficacy of oxaliplatin-based adjuvant chemotherapy in older patients with stage III colon cancer: An ACCENT/IDEA pooled analysis of 12 trials
140. 321P A comprehensive predicting model of recurrence in stage III colon cancer from PETACC-8 trial
141. Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial
142. Combination of folinic acid, 5-fluorouracil bolus and infusion, and cisplatin (LV5FU2-P regimen) in patients with advanced gastricor gastroesophageal junction carcinoma
143. Momentum distributions of projectile spectators: a new tool to investigate the equation of state of nuclear matter
144. Dynamics of spallation reactions investigated from production cross sections of residual nuclei in collisions induced by 238U at 1 A·GeV on proton and deuterium
145. The MIROX Regimen: Intensive systemic chemotherapy combined with surgical treatment of colorectal cancer metastases. Results of a phase II study: 3592
146. Combination of folinic acid, 5-fluorouracil bolus and infusion, and cisplatin (LV5FU2-P regimen) in patients with advanced gastric or gastroesophageal junction carcinoma
147. SO-18 Reinforcing clinical outcomes with patient-reported QoL outcomes in patients with mCRC receiving FTD/TPI: Pooled analysis of PRECONNECT and TALLISUR studies
148. P-81 Phase 3 study of MK4280A (coformulated favezelimab and pembrolizumab) versus standard of care in previously treated PD-L1–positive metastatic colorectal cancer (mCRC)
149. P-22 Phase III study (daNIS-2) of the anti–TGF-β monoclonal antibody NIS793 with nab-paclitaxel/gemcitabine vs nab-paclitaxel/gemcitabine alone in patients with first-line metastatic pancreatic ductal adenocarcinoma
150. P-17 Real-life use and long-term effectiveness results from CIREL – the multi-centre, observational study on irinotecan-eluting transarterial chemoembolization in CRLM
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.